Athsma
Conditions
Interventions
Observation group :None
Sponsors
The First Affiliated Hospital of Air Force Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Aged >= 18 years, regardless of gender; 2. A definite diagnosis of severe asthma and meeting the diagnostic criteria for severe eosinophilic asthma (SEA): with at least one piece of evidence for eosinophilia (baseline blood eosinophil count >= 150/µL or sputum eosinophil proportion >= 3%), and simultaneously conforming to the diagnostic criteria for severe asthma specified in the Guidelines for the Diagnosis and Treatment of Severe Asthma (2024 Edition); 3. Having received benralizumab treatment with a definite time of the first administration and a treatment duration of >= 6 months; 4. Accessible to complete baseline data (demographic data, pulmonary function, laboratory tests, medical history, etc.) and follow-up data for at least 6 months.
Exclusion criteria
Exclusion criteria: 1. Patients with hypersensitivity to benralizumab or any of its components; 2. Patients complicated with other severe pulmonary diseases (e.g., chronic obstructive pulmonary disease, bronchiectasis, pulmonary fibrosis, active pulmonary tuberculosis, pulmonary malignant tumors, etc.) that may interfere with the assessment of pulmonary function and treatment efficacy; 3. Patients complicated with severe heart, liver, kidney, hematologic or immune system diseases, or other severe illnesses that may affect the study results (e.g., severe infections, malignant tumors, autoimmune diseases, etc.); 4. Patients with a history of or current use of other anti-asthma biological agents (e.g., mepolizumab, omalizumab, etc.) who have not completed an adequate washout period (>= 30 days); 5. Patients with extremely poor treatment compliance (medication non-adherence rate >= 30%), or those who are unable to complete follow-up, have excessive data missing for various reasons, and thus cannot be assessed for treatment efficacy and safety; 6. Pregnant or lactating women, or women planning to become pregnant during the study period; 7. Patients with mental disorders or cognitive impairment who are unable to cooperate with questionnaire assessments and follow-up procedures.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Annual acute exacerbation rate;percentage of predicted FEV1;ACQ-5 score; | — |
Secondary
| Measure | Time frame |
|---|---|
| blood eosinophil count;oral corticosteroid reduction rate;rescue medication use frequency;pulmonary ventilation function improvement rate; | — |
Countries
China
Contacts
Public ContactShuoyao Qu
The First Affiliated Hospital of Air Force Medical University
Outcome results
None listed